Transgenic models of ALS caused by VAPB mutation
Transgenic models of ALS caused by VAPB mutation
批准号:
7466543
负责人:
ZUOSHANG XU
金额:
$35.55万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2013-03-31
关键词:
AdultAffectAmyotrophic Lateral SclerosisAnimal ModelAnimalsCellsCessation of lifeCisplatin/Doxorubicin/Melphalan/TeniposideClinicalCultured CellsCytoplasmDataDiseaseDisease modelDominant-Negative MutationEndoplasmic ReticulumFamilial Amyotrophic Lateral SclerosisFamilyFutureGene MutationGenesHumanIn VitroMediatingMicroRNAsMicrogliaModelingMotor NeuronsMusMuscular AtrophyMutationNerve DegenerationNeurodegenerative DisordersNeurogliaNeuronsOpen Reading FramesParalysedPathologyPhenylalanineProtein OverexpressionProteinsRNA InterferenceRoleSOD1 geneSiteSkeletal MuscleSymptomsTechnologyTestingTherapeuticTransgenic AnimalsTransgenic MiceTransgenic ModelTransgenic Organismsage relatedbaseclinical phenotypedesigndesign and constructiongain of functionhuman VAPA proteinin vivoloss of functionmotor neuron degenerationmouse modelmutantpre-clinicalprotein Breceptorresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes motor neuron degeneration, skeletal muscle atrophy, paralysis and death. Our long term objective is to understand the disease mechanism and develop a cure. At present, the only robust model for typical ALS is mice that express mutant SOD1. Recently, a mutation in VAMP associated protein B (VAPB) gene has been identified to cause motor neuron degeneration and ALS. The clinical symptom of ALS as a result of the VAPB mutation is variable and includes both typical and atypical cases. All, however, is adult onset. Based on in vitro data, the predominant hypothesis regarding the mechanism whereby mutant VAPB induces ALS is that the mutation leads to a dominant negative activity. However, no in vivo data is available. In addition, other possibilities, such as dominant gain-of-function and loss-of-function have not been ruled out. We propose to differentiate these three possibilities using transgenic approaches to overexpress the mutant VAPB and to silence the mouse VAPB using transgenic RNAi. The combined data from these two approaches will unequivocally determine which one of these three mechanisms is true. Because our transgenic constructs are designed to be Cre-inducible, these transgenic mice can be used to investigate the roles of mutant VAPB expression in motor neuron and non-motor neuron cells in the future by crossing with mice that express Cre in various specific cells (neurons, glia and microglia). Furthermore, we propose complementary experiments in cultured cells to dissect the function of VAPB and the altered function in mutant VAPB. These experiments will enhance our understanding of mechanisms of motor neuron degeneration and establish a second line of adult onset transgenic model for ALS, which can be used for preclinical analysis of therapeutic strategies for ALS. RELEVANCE: A VAPB gene mutation causes amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease without a cure. We propose to establish cell culture and transgenic mouse models to investigate how the VAPB mutation causes neuronal degeneration. Once established, these models can be used for pre-clinical tests of therapeutic compounds.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS
-
批准号:10399654
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2021
-
负责人:ZUOSHANG XU
-
依托单位:
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS
-
批准号:10605239
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2021
-
负责人:ZUOSHANG XU
-
依托单位:
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS
-
批准号:10298171
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2021
-
负责人:ZUOSHANG XU
-
依托单位:
A new approach to immunotherapy for ALS
-
批准号:9808031
-
项目类别:
-
资助金额:$46.06万
-
财政年份:2019
-
负责人:ZUOSHANG XU
-
依托单位:
An in vivo approach to understanding mutant PFN1 toxicity on motor neurons
-
批准号:9893934
-
项目类别:
-
资助金额:$36.64万
-
财政年份:2017
-
负责人:ZUOSHANG XU
-
依托单位:
A new approach to modeling ALS based on TBK1 mutation in mice
-
批准号:9275555
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2016
-
负责人:ZUOSHANG XU
-
依托单位:
Does TDP-43 dysfunction in astrocytes trigger motor neuron degeneration?
-
批准号:9110354
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2015
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling Mutant Profilin 1 Toxicity and ALS in vivo
-
批准号:8490556
-
项目类别:
-
资助金额:$20.8万
-
财政年份:2013
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:8055338
-
项目类别:
-
资助金额:$34.84万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:7567500
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:7799908
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling TDP-43 Dysfunction in vivo
-
批准号:7451906
-
项目类别:
-
资助金额:$17.77万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:8265853
-
项目类别:
-
资助金额:$34.84万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Understanding CLIM2 functions in vivo using transgenic RNAi
-
批准号:7472089
-
项目类别:
-
资助金额:$20.43万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling Progranulin hypomorphism for FTD in mice
-
批准号:7362633
-
项目类别:
-
资助金额:$17.77万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling Progranulin hypomorphism for FTD in mice
-
批准号:7495557
-
项目类别:
-
资助金额:$21.33万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Silencing mutant SOD1 in vivo for treatment of ALS
-
批准号:7247798
-
项目类别:
-
资助金额:$22.82万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Reverse genetics using RNAi in non-mouse mammals
-
批准号:7212491
-
项目类别:
-
资助金额:$16.66万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Silencing mutant SOD1 in vivo for treatment of ALS
-
批准号:7385006
-
项目类别:
-
资助金额:$17.84万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Reverse genetics using RNAi in non-mouse mammals
-
批准号:7343224
-
项目类别:
-
资助金额:$19.59万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
海外基金